ALDEYRA

Pharmaceutical agents for Reactive Aldehyde Species (RASP) inhibition, Dihydrofolate Reductase Inhibition, and by Heat Shock Protein 90 and chaperome Inhibition for the treatment of immune-mediated diseases, dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, Sjögren-Larsson Syndrome, immune-mediated ocular diseases, systemic diseases, proliferative vitreoretinopathy, retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer; pharmaceuticals for use in treatment of immune-mediated diseases; pharmaceuticals for use in treating dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome; pharmaceuticals for treating immune-mediated ocular diseases and systemic diseases; pharmaceuticals for treating proliferative vitreoretinopathy, retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer